|Bid||13.30 x 1400|
|Ask||20.00 x 800|
|Day's range||15.05 - 16.99|
|52-week range||4.69 - 17.99|
|Beta (5Y monthly)||1.64|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Shares of Ultragenyx (RARE) rise 23.4% after releasing positive top-line data from the phase I/II study of its gene therapy candidate DTX301 for the treatment of OTC deficiency.
If you own shares in Cue Biopharma, Inc. (NASDAQ:CUE) then it's worth thinking about how it contributes to the...
The Zacks Analyst Blog Highlights: EverQuote, Cassava Sciences, Fulgent Genetics, Teekay Tankers and Cue Biopharma
Does Cue Biopharma, Inc. (CUE) have what it takes to be a top stock pick for momentum investors? Let's find out.
The biotech sector recovers on the back of rising M&A activities and pipeline successes in 2019 after a dismal 2018. Here we discuss five biotech companies recording impressive growth.
Cue Biopharma, Inc. (CUE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! It is doubtless a positive to see that the Cue Biopharma, Inc. (NASDAQ:CUE) share price has gained...
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip side of that is that there are more Read More...